| Route/form | Estrogen | Dosage | Ref(s) |
|---|---|---|---|
| Oral | Estradiol | 10 mg 3x/day AI-resistant: 2 mg 1–3x/day |
[1][2] [1][3] |
| Estradiol valerate | AI-resistant: 2 mg 1–3x/day | [1][3] | |
| Conjugated estrogens | 10 mg 3x/day | [4][5][6][7] | |
| Ethinylestradiol | 0.5–1 mg 3x/day | [5][1][8][7] | |
| Diethylstilbestrol | 5 mg 3x/day | [5][9][10] | |
| Dienestrol | 5 mg 3x/day | [8][7][10] | |
| Dimestrol | 30 mg/day | [4][7][10] | |
| Chlorotrianisene | 24 mg/day | [4][10] | |
| IM or SC injection | Estradiol benzoate | 5 mg 2–3x/week | [8][11][9][12] |
| Estradiol dipropionate | 5 mg 2–3x/week | [8][9][13][12] | |
| Estradiol valerate | 30 mg 1x/2 weeks | [11] | |
| Polyestradiol phosphate | 40–80 mg 1x/4 weeks | [14][15] | |
| Estrone | 5 mg ≥3x/week | [16] | |
| Notes: (1) Only in women who are at least 5 years postmenopausal.[1] (2) Dosages are not necessarily equivalent. | |||
Template documentationSee also
- Template:Estrogen dosages for prostate cancer
- Template:Androgen/anabolic steroid dosages for breast cancer
- Template:Estrogen dosages for menopausal hormone therapy
- Template:Medications and dosages used in hormone therapy for transgender women
References
- ^ a b c d e Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017). "The use of high-dose estrogens for the treatment of breast cancer". Maturitas. 95: 11–23. doi:10.1016/j.maturitas.2016.10.010. PMID 27889048.
- ^ "ESTRACE® TABLETS (estradiol tablets, USP) FDA label" (PDF). 2005.
- ^ a b Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ (January 2014). "Breast cancer: current and future endocrine therapies". Mol. Cell. Endocrinol. 382 (1): 695–723. doi:10.1016/j.mce.2013.08.001. PMID 23933149.
- ^ a b c Green RB, Sethi RS, Lindner HH (July 1964). "Treatment of advanced carcinoma of the breast: Progress in therapy during the past decade". Am. J. Surg. 108: 107–21. doi:10.1016/0002-9610(64)90094-7. PMID 14182428.
- ^ a b c Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1.
- ^ "Premarin® (conjugated estrogens tablets, USP) FDA label" (PDF). 2003.
- ^ a b c d Van Winkle, Walton (1949). "Council on Pharmacy and Chemistry. Estrogens and Androgens in Mammary Cancer". JAMA: The Journal of the American Medical Association. 140 (15): 1214. doi:10.1001/jama.1949.02900500022007. ISSN 0098-7484.
- ^ a b c d Kahr, Ernst (1966). "Die Allgemeinbehandlung" [General Treatment]. Der Inoperable Krebskranke: Möglichkeiten der Therapie in Klinik und Praxis [The Inoperable Cancer Patient: Possibilities of Therapy in Clinic and Practice]. Springer-Verlag. pp. 104–155. doi:10.1007/978-3-642-86140-6_4. ISBN 978-3-642-86140-6.
- ^ a b c Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli; David G. Johns (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
- ^ a b c d Nathanson IT, Kelley RM (January 1952). "Hormonal treatment of cancer". N. Engl. J. Med. 246 (5): 180–9, concl. doi:10.1056/NEJM195201312460505. PMID 14890833.
- ^ a b Dobson L (August 1962). "The management of metastatic breast cancer". Surg. Clin. North Am. 42: 861–76. doi:10.1016/S0039-6109(16)36728-7. PMID 13886800.
- ^ a b Martz G (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 39–. ISBN 978-3-642-86282-3.
- ^ Committee on Research, AMA (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of nine hundred forty-four patients". Journal of the American Medical Association. 172 (12): 1271. doi:10.1001/jama.1960.03020120049010. ISSN 0002-9955.
- ^ "Estradurin® (polyestradiol phosphate) information and labels". Pharmanovia.
- ^ Ostrowski MJ, Jackson AW (1979). "Polyestradiol phosphate: a preliminary evaluation of its effect on breast carcinoma". Cancer Treat Rep. 63 (11–12): 1803–7. PMID 393380.
- ^ "Estrone suspension FDA review" (PDF). 1979.